The Prevalence of Dietary Supplements That Claim Estrogen-like Effects in Japanese Women

Tsuyoshi Chiba 1,*, Yuko Tousen 1, Chiharu Nishijima 1 and Keizo Umegaki 2

1 Department of Food Function and Labeling, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo 162-8363, Japan
2 Department of Food Safety and Management, Showa Women’s University, Tokyo 154-8533, Japan
* Correspondence: tyschiba@nibiono.go.jp; Tel.: +81-3-3203-8063

Abstract: Recently, adverse events, such as irregular vaginal bleeding and menstrual disorders, associated with the use of dietary supplements containing Pueraria mirifica, have been reported in Japan. P. mirifica contains phytoestrogens, such as deoxymiroestrol and miroestrol. Therefore, we investigated the use of supplements that claim to have estrogen-like effects (i.e., estrogen-like supplements) in Japanese women aged from 15 to 69 years old in an online survey. The prevalence of estrogen-like supplement use was 5%, accounting for approximately 15% of the sample, including ex-users. The majority of the users were in their 40s and 50s, mainly using these supplements for the treatment of menopausal symptoms. In contrast, the younger generation mainly used them for beauty purposes, such as weight loss, mastogenic effects, and skin care. Many of them visited a clinic or took medicines for menstrual-related troubles. In all age groups, soybeans/isoflavones were the most commonly used, followed by equol and placenta. Participants in their teens and 20s also used P. mirifica. Among them, 16.2% had experienced adverse events, including irregular vaginal bleeding, breast swelling and pain, and heavy menstruation. In conclusion, estrogen-like supplement use is associated with adverse events; thus, it is necessary to pay attention to the use of these supplement. Furthermore, because the purpose of use differs depending on generation, caution according to each generation is necessary.

Keywords: dietary supplements; Pueraria mirifica; estrogen; adverse events

1. Introduction

Dietary supplements are used for a wide range of purposes other than nutritional supplementation, and the purpose differs depending on the user’s characteristics, such as gender, age, and health condition. It has been reported that the prevalence of dietary supplement use is higher in women compared with men [1,2]. Specifically, women are more likely than men to use dietary supplements for weight loss and beauty purposes [3]. Recently, many products targeting women that claim a mastogenic effect via an estrogen-like action are commercially available on the market. One of the major ingredients of these products in Japan is Pueraria mirifica, which contains phytoestrogens, such as deoxymiroestrol and miroestrol. Phytoestrogens are plant-derived compounds that have a similar structure to estradiol and have weak affinity to the estrogen receptor [4]. However, it has been reported that the estrogenic activity of deoxymiroestrol and miroestrol is almost the same as that of 17beta-estradiol [5]; therefore, products containing P. mirifica might possess estrogen-like effects. Indeed, the effects of P. mirifica on the reproductive organs, bones, cardiovascular diseases, and other symptoms related to estrogen deficiency in menopausal women have been studied [6]. In contrast, there have been a series of reports of adverse events related to the use of products containing P. mirifica among young women in Japan, and the National Consumer Affairs Center of Japan cautions consumers on P. mirifica [7,8]. This caution from the National Consumer Affairs Center of Japan is mainly for young women, but some...
products containing *P. mirifica* claim efficacy against menopausal symptoms, meaning that middle-aged and older women might also use these products. In fact, adverse events have been observed in a clinical trial using *P. mirifica* in peri-menopausal women [9].

Post-menopausal women exhibit decreased levels of female hormone secretion, making the estrogenic effects of these supplements attractive. In addition to *P. mirifica*, other supplements that claim estrogen-like effects are used for the purpose of alleviating symptoms of menopausal disorders. In Japan, isoflavones derived from soybeans, which have estrogenic effects, are the most popular ingredients taken by such women, because Japanese people are familiar with soy products, such as tofu, miso, and natto [10,11]. Numerous studies have been conducted on the benefits of soy-based isoflavone intake; a systematic review revealed that an increased soy isoflavone intake increases bone mineral density [12], reduces the risk of breast cancer in pre- and post-menopausal women [13], and decreases the prevalence of menopausal symptoms such as hot flashes and vaginal dryness [14,15]. However, soy isoflavone intake has been shown not to affect other menopausal symptoms, such as vaginal atrophy index and night sweats [15,16]. In addition, around 200 million people worldwide [17], and 12.8 million people in Japan [18], are affected by osteoporosis. The association between menopause and osteoporosis and the role of estrogen in maintaining bone mineral density are well known [19]. Estrogen treatment is standard for preventing osteoporosis [20], but there are concerns that prolonged estrogen treatment in postmenopausal women may increase the risk of ovarian cancer [21,22]. In this regard, peri-menopausal women prefer to use supplements that claim estrogen-like effects to prevent osteoporosis.

Compared with young people, more middle-aged and older aged people prefer dietary supplementation. In addition, a significant proportion of people in this population take medicines that include estrogen preparations [23,24], and polypharmacy is a major concern among these populations [25]. In this regard, these generations should be aware of not only the dietary supplement itself, but also the interaction between dietary supplements and drugs. In particular, patients receiving hormone-replacement therapy for menopausal disorders should be concerned about the interaction between hormones and dietary supplements [26]. If dietary supplements contain ingredients that have estrogen-like effects, additive or synergistic effects may be induced in patients undergoing hormone-replacement therapy. However, the status of the use of estrogen-like supplements in women has not been clarified. In this study, we focused on supplements claiming to have female hormone-like effects (i.e., estrogen-like supplements), and investigated the use of estrogen-like supplements by women in each age group, as well as any adverse events.

2. Materials and Methods

2.1. Participants and Procedures

An online cross-sectional questionnaire survey was conducted by Cross Marketing Inc. (Tokyo, Japan) from 24 September to 2 October 2019. This study was conducted with the approval of the Research Ethics Committee of the National Institutes of Biomedical Innovation, Health and Nutrition (No. 194-2, approved on 18 July 2019), Showa Women’s University (No. 19-15, approved on 21 June 2019), and in accordance with the Declaration of Helsinki. The questions were presented to the research company, who then conducted an Internet survey, collected the survey results, and anonymized the personal information to deliver data which could not be identified. Females from 15 to 69 years of age were registered with the research company as survey monitors. An email with a survey cooperation request and a webpage link to the survey was sent to computer-randomized monitors. An explanation of this study was provided at the beginning of the survey page, and only those individuals who agreed to participate answered the questionnaire. Complete responses were collected on a first come, first served basis, until the numbers reached the quotas for age. A preliminary survey was conducted to elucidate estrogen-like supplement usage and gestational and menopause conditions. Then, the actual survey was conducted on 1200 estrogen-like supplement users from the preliminary survey by age group. The actual survey contained questions about the purpose of dietary supplement use, the major ingre-
dients of dietary supplements, and the experience of adverse events. The questionnaire in this survey is presented as Supplementary Materials.

2.2. Statistical Analysis

Differences in the distribution among age groups were compared using a chi-squared ($\chi^2$) test using IBM SPSS Statistics ver. 28.0.1.0 (IBM Corporation, Armonk, NY, USA). A $p$-value of <0.05 was considered statistically significant. Estrogen-like supplement usage is influenced by consumers’ status (age, gestational condition, and menopause condition). These factors were entered into a bivariate logistic regression, and candidate variables were entered into a multivariable logistic regression model. To identify factors of the prevalence of estrogen-like supplement usage, multivariable logistic regression was conducted, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using EZR ver. 4.0.3 (Saitama, Japan), which is a modified version of R commander designed to add statistical functions frequently used in biostatistics.

3. Results

3.1. Characteristics of the Participants

To study estrogen-like supplement users, a preliminary survey was conducted on 61,021 females aged 15–69 years (Table 1). Regarding gestational condition, 2.8% were pregnant and 4.0% were lactating. In terms of menopause, 1.7% were before the first menstruation, 66.4% were premenopausal, and 31.9% were post-menopausal.

Table 1. Characteristics of the participants.

|                             | Preliminary Survey | Actual Survey |
|-----------------------------|--------------------|---------------|
|                             | $n$    | %    | $n$    | %    |
| Total                       | 61,021 |      | 1200   |      |
| Age                         |        |      |        |      |
| 10s                         | 3997   | 6.6  | 130    | 10.8 |
| 20s                         | 9610   | 15.7 | 203    | 16.9 |
| 30s                         | 12,930 | 21.2 | 217    | 18.1 |
| 40s                         | 14,830 | 24.3 | 217    | 18.1 |
| 50s                         | 12,866 | 21.1 | 217    | 18.1 |
| 60s                         | 6788   | 11.1 | 216    | 18.0 |
| Gestational condition       |        |      |        |      |
| None                        | 56,860 | 93.2 | 1118   | 93.2 |
| Pregnant                    | 1726   | 2.8  | 44     | 3.7  |
| Lactating                   | 2435   | 4.0  | 38     | 3.2  |
| Menopause condition         |        |      |        |      |
| In 30s                      | 846    | 1.5  | 24     | 2.1  |
| In 40s                      | 5304   | 8.9  | 93     | 8.3  |
| In 50s                      | 11,363 | 20.0 | 284    | 25.4 |
| In 60s                      | 648    | 1.1  | 18     | 1.6  |
| Premenopausal               | 37,751 | 66.4 | 686    | 61.4 |
| Before first menstruation   | 948    | 1.7  | 13     | 1.2  |

1 10s, aged from 15 to 19 years old.

3.2. The Prevalence of Dietary Supplement Use

The prevalence of dietary supplement use is shown in Table 2. Regarding any type of dietary supplement, 28.9% of the participants were currently using dietary supplements, whereas 18.8% used to use dietary supplements. In terms of estrogen-like supplements, 5.0% of the participants were currently using estrogen-like supplements, accounting for 10.5% of the dietary supplement users. Additionally, 2.8% of the participants had used estrogen-like supplements within the last year, accounting for 5.8% of the dietary supplement users. Then, the 1200 participants who were using or had used estrogen-like supplements progressed to
the actual survey (Table 1). The characteristics of the participants in the actual survey were almost the same as those in the preliminary survey.

Table 2. The prevalence of dietary supplement use.

|                               | n   | %   | %   |
|-------------------------------|-----|-----|-----|
| Any dietary supplements 1     |     |     |     |
| I am currently using it       | 17,658 | 28.9 |     |
| I used to use it, but not now | 11,495 | 18.8 |     |
| I have never used it          | 31,868 | 52.2 |     |
| Estrogen-like supplements 2   |     |     |     |
| I am currently using it       | 3057 | 5.0 | 10.5 |
| I used to use it within the last year | 1704 | 2.8 | 5.8 |
| I used to use it over a year ago | 4135 | 6.8 | 14.2 |
| I have never used it          | 20,257 | 85.4 | 69.5 |

1 n = 61,021; 2 n = 29,153, including dietary supplement users and ex-users; 3 ratio of dietary supplement users to ex-users (29,153); 4 sum of non-users of estrogen-like supplements (20,257) and any type of dietary supplements (31,868).

3.3. Factors Associated with Estrogen-like Supplement Use

Estrogen-like supplement use might be associated with one’s hormonal condition. Thus, we conducted a logistic regression analysis to identify the factors influencing estrogen-like supplement usage (Table 3). No multicollinearity among the independent variables was suggested by the correlation analysis. In this survey, age, gestational condition, menstruation, menstruation-related problems, dedication for menstruation-related problems, and subjective symptoms suggestive of menopause were identified as significant factors. Among these factors, only menstruation suppressed estrogen-like supplement usage.

Table 3. Factors associated with estrogen-like supplement use.

|                                | Univariable OR (95% CI) | p-Value | Multivariable OR (95% CI) | p-Value |
|--------------------------------|-------------------------|---------|---------------------------|---------|
| Age                            |                         |         |                           |         |
| 10s                            | Reference               |         | Reference                 |         |
| 20s                            | 1.67 (1.32–2.11)        | <0.001  | 1.52 (1.20–1.93)          | <0.001  |
| 30s                            | 1.86 (1.48–2.33)        | <0.001  | 1.72 (1.37–2.17)          | <0.001  |
| 40s                            | 2.79 (2.24–3.48)        | <0.001  | 2.35 (1.88–2.94)          | <0.001  |
| 50s                            | 3.46 (2.78–4.31)        | <0.001  | 2.87 (2.27–3.64)          | <0.001  |
| 60s                            | 1.78 (1.39–2.27)        | <0.001  | 2.09 (1.60–2.73)          | <0.001  |
| Gestational condition          |                         |         |                           |         |
| None                           | Reference               |         | Reference                 |         |
| Pregnant                       | 1.11 (0.90–1.37)        | 0.313   | 2.10 (1.65–2.67)          | <0.001  |
| Lactating                      | 0.58 (0.46–0.73)        | <0.001  | 1.06 (0.8–1.39)           | 0.656   |
| Menstruation                   |                         |         |                           |         |
| No                             | Reference               |         | Reference                 |         |
| Yes                            | 0.87 (0.81–0.94)        | <0.001  | 0.75 (0.64–0.86)          | 0.778   |
| Menstruation-related Problem   |                         |         |                           |         |
| No                             | Reference               |         | Reference                 |         |
| Yes                            | 1.29 (1.20–1.38)        | <0.001  | 1.40 (1.24–1.58)          | <0.001  |
| Dedication for menstruation-related problems |                 |         |                           |         |
| No                             | Reference               |         | Reference                 |         |
| See a doctor                   | 2.74 (2.32–3.25)        | <0.001  | 2.34 (1.96–2.79)          | <0.001  |
| Take medicine                  | 1.71 (1.53–1.91)        | <0.001  | 1.84 (1.63–2.09)          | <0.001  |
| Both doctor and medicine       | 2.20 (1.85–2.62)        | <0.001  | 2.21 (1.84–2.66)          | <0.001  |
| Subjective symptoms suggestive of menopause |             |         |                           |         |
| No                             | Reference               |         | Reference                 |         |
| Yes                            | 3.21 (2.98–3.46)        | <0.001  | 2.54 (2.34–2.75)          | <0.001  |

n = 61,021.
3.4. Health Conditions among Estrogen-like Supplement Users

Data on health conditions in terms of menstruation are shown in Table 4. Only 19.2% of the premenopausal participants did not have any problem with menstruation, whereas the other 80.8% expressed some problems, such as feeling irritable, depressed, or sleepy before menstruation (46.6%), irregular cycles (42.4%), and severe pain during menstruation (42.3%). In this situation, 11.3% of them were seeing a doctor and 20.8% of them were taking medicine for menstrual-related symptoms (Table 5). In addition, 10.0% of them had subjective symptoms suggestive of menopause, and they were visiting a clinic, whereas 29.2% of them had subjective symptoms suggestive of menopause, but they were not visiting a clinic (Table 6).

Table 4. Menstruation-related problems among estrogen-like supplement users.

| Problem                                      | n   | %    |
|----------------------------------------------|-----|------|
| None                                         | 132 | 19.2 |
| Irregular cycles                             | 291 | 42.4 |
| Heavy menstrual bleeding                      | 139 | 20.3 |
| Severe pain during menstruation (abdominal pain, headaches, etc.) | 290 | 42.3 |
| Feeling irritable, depressed, or sleepy before menstruation | 320 | 46.6 |
| Other                                        | 33  | 4.8  |

*n = 686.

Table 5. Statement of medication for menstruation-related symptoms among estrogen-like supplement users.

| Medication                                      | n   | %    |
|-----------------------------------------------|-----|------|
| Seeing a doctor for menstruation-related symptoms | 126 | 11.3 |
| Taking medicine for menstruation-related symptoms | 233 | 20.8 |
| Seeing a doctor other than menstruation-related symptoms | 141 | 12.6 |
| Taking medicine other than menstruation-related symptoms | 183 | 16.4 |
| No medication                                 | 664 | 59.4 |

*n = 1118, excluding pregnancy and lactating participants.

Table 6. Subjective symptoms suggestive of menopause among estrogen-like supplement users.

| Symptom                                           | n   | %    |
|---------------------------------------------------|-----|------|
| I have subjective symptoms and am visiting a clinic | 112 | 10.0 |
| I have subjective symptoms but am not visiting a clinic | 326 | 29.2 |
| I used to have symptoms, but I am better now       | 196 | 17.5 |
| I have never experienced any symptoms              | 484 | 43.3 |

*n = 1118, excluding pregnancy and lactating participants.

3.5. The Purpose of Estrogen-like Supplement Use

The purpose of estrogen-like supplement use is shown in Table 7. The main purpose was “Anti-aging (36.8%)”, which was higher in older generations compared with younger generations. Other key purposes were “Treatment for menopause symptom (33.5%)”, “Skin care (31.0%)”, and “Treatment for menstruation-related symptoms (24.5%)”, and “Weight loss (20.0%)”. Except for “Treatment of disease”, there were significant differences among generations. “Weight loss”, “Mastogenic effect”, “Skin care”, and “Treatment for menstruation-related symptoms” were higher in younger generations; on the other hand, “Treatment for menopause symptoms”, “Prevention of diseases”, and “Anti-aging” were higher in older generations.
Table 7. The purpose of estrogen-like supplement use.

|                          | n  | All 1200 | 10s 130 | 20s 203 | 30s 217 | 40s 217 | 50s 217 | 60s 216 | p-Value |
|--------------------------|----|----------|---------|---------|---------|---------|---------|---------|---------|
| Weight loss              | 20.0 | 33.8    | 34.5    | 25.3    | 12.9    | 9.7     | 10.2    | <0.001  |
| Mastogenic effect        | 15.7 | 40.0    | 37.4    | 15.2    | 6.5     | 3.7     | 2.3     | <0.001  |
| Skincare                 | 31.0 | 34.6    | 42.9    | 40.6    | 28.1    | 19.8    | 22.2    | <0.001  |
| Treatment for menstruation-related symptoms | 24.5 | 34.6 | 35.0 | 39.6 | 31.3 | 9.2 | 1.9 | <0.001 |
| Treatment for menopause symptoms | 33.5 | 7.7 | 12.3 | 25.3 | 51.6 | 66.8 | 25.5 | <0.001 |
| Prevention of diseases   | 11.4 | 5.4    | 7.9     | 15.2    | 8.8     | 12.9    | 15.7    | 0.006   |
| Treatment of diseases    | 4.3  | 3.8     | 4.9     | 6.5     | 3.2     | 2.8     | 4.6     | 0.470   |
| Anti-aging               | 36.8 | 3.8    | 15.3    | 38.2    | 42.4    | 43.3    | 63.4    | <0.001  |
| No special reason        | 4.8  | 3.8     | 3.9     | 5.5     | 5.1     | 3.7     | 6.5     | 0.734   |
| Other                    | 3.1  | 0.8     | 3.4     | 5.1     | 3.2     | 2.3     | 2.8     | 0.325   |

n = 1200. Multiple answers. The results are shown as percentages (%). The difference among generations was examined using a chi-squared ($\chi^2$) test.

3.6. The Major Ingredient of Estrogen-like Supplements

The main ingredients of estrogen-like supplements which the participants used are shown in Table 8. The most popular ingredient was soybeans/isoflavones (43.3%). The second most popular ingredient was equol (24.4%), which is a metabolite of daidzein by enterobacterium. The third most popular ingredient was the placenta (22.7%), and the prevalence of these three ingredients was higher in older generations compared with younger generations. The other ingredients comprised less than 10%, although the prevalence of P. mirifica was 5.2% and was higher in the younger generations compared with the older generations.

Table 8. The major ingredients of estrogen-like supplements.

|                          | n  | All 1200 | 10s 130 | 20s 203 | 30s 217 | 40s 217 | 50s 217 | 60s 216 | p-Value |
|--------------------------|----|----------|---------|---------|---------|---------|---------|---------|---------|
| Soybeans/isoflavones     | 43.3 | 28.5    | 40.9    | 44.2    | 45.2    | 46.5    | 48.1    | 0.008   |
| Equol                    | 24.4 | 3.1     | 10.3    | 18.0    | 34.1    | 41.0    | 30.6    | <0.001  |
| Red clover               | 2.9  | 1.5     | 6.4     | 1.8     | 4.1     | 1.8     | 1.4     | 0.014   |
| Kudzu vinem              | 2.7  | 2.3     | 3.9     | 3.7     | 2.8     | 0.9     | 2.3     | 0.433   |
| Chaste tree (Chaste berry)| 3.4  | 3.1     | 4.9     | 5.5     | 3.7     | 2.3     | 0.9     | 0.097   |
| Black cohosh             | 2.4  | 1.5     | 3.9     | 4.6     | 2.3     | 1.4     | 0.5     | 0.045   |
| Pueraria mirifica        | 5.2  | 6.9     | 10.8    | 6.5     | 3.7     | 2.8     | 1.4     | <0.001  |
| Placenta                 | 22.7 | 13.1    | 21.2    | 23.0    | 23.5    | 19.4    | 31.9    | 0.002   |
| French marine pine bark extract | 1.7 | 0.0 | 2.5 | 1.4 | 2.3 | 2.8 | 0.5 | 0.210 |
| Other                    | 11.1 | 13.1 | 7.9 | 12.9 | 10.6 | 12.9 | 9.7 | 0.473 |

n = 1200. Multiple answers. The results are shown as percentages (%). The difference among generations was examined using a chi-squared ($\chi^2$) test.

3.7. Statement of Estrogen-like Supplement Use

In terms of frequency, most of the participants used estrogen-like supplements for five to seven days a week (69.6%), followed by three to four days a week (12.2%), and one to two days a week (9.8%) (Table 9). Regarding duration, most of the participants had used estrogen-like supplements for more than one year (34.3%), followed by one to three months (17.8%) and three to six months (14.3%) (Table 10).
3.8. Information Sources and Ways to Obtain Estrogen-like Supplements

The information sources pertaining to estrogen-like supplements are shown in Table 11. The most popular information source was the Internet (58.5%), then television or radio (26.8%), then family, friends, or acquaintances (19.8%). There were significant differences among generations in information sources, but only SNS showed a clear tendency, in that it was higher in the younger generations and decreased age-dependently. According to information source, most obtained estrogen-like supplements via the Internet (57.5%), followed by a pharmacy or drug store (44.2%) and by mail order (9.9%) (Table 12). There was a tendency toward more of the younger generations obtaining estrogen-like supplements at physical stores, such as a pharmacy or drug store, clinic, or supermarket/convenience store compared with the older generations.

Table 11. Information sources of estrogen-like supplements.

| Information Source                                      | All | 10s | 20s | 30s | 40s | 50s | 60s | p-Value |
|---------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|---------|
| Television or radio                                     | 26.8| 23.1| 22.2| 27.2| 22.6| 30.4| 33.8| 0.035   |
| Newspaper, magazine, or advertisement                   | 16.5| 12.3| 13.3| 15.7| 11.5| 17.5| 26.9| <0.001  |
| Internet                                                | 58.5| 49.2| 50.2| 56.7| 65.4| 66.8| 58.3| <0.001  |
| SNS (LINE, Facebook, Twitter, and Instagram)            | 18.8| 34.6| 31.5| 30.0| 12.4| 6.5 | 4.6 | <0.001  |
| Specialists (doctors, pharmacists, and dieticians)      | 10.8| 10.8| 12.8| 11.1| 12.9| 8.3 | 8.8 | 0.523   |
| Beauty salon or therapist                               | 4.2 | 3.8 | 9.4 | 5.1 | 2.8 | 1.8 | 2.3 | 0.001   |
| Store clerks in pharmacies or drugstores                | 14.1| 16.2| 14.3| 16.1| 15.7| 10.6| 12.5| 0.508   |
| Point-of-purchase adverts                               | 8.3 | 1.5 | 7.9 | 12.0| 11.1| 9.7 | 5.1 | 0.004   |
| Product packaging                                       | 16.6| 6.9 | 14.3| 19.4| 22.1| 16.6| 16.2| 0.008   |
| Family, friends, or acquaintances                       | 19.8| 26.9| 18.2| 19.8| 16.6| 16.6| 23.1| 0.116   |
| Other                                                   | 1.9 | 0.0 | 1.0 | 1.8 | 2.3 | 1.8 | 3.7 | 0.197   |

n = 1200. Multiple answers. The difference among generations was examined using a chi-square (χ²) test.
Table 12. Ways of obtaining estrogen-like supplements.

|                          | n   | 10s | 20s | 30s | 40s | 50s | 60s | p-Value |
|--------------------------|-----|-----|-----|-----|-----|-----|-----|---------|
| Pharmacy or drug store   | 44.2| 52.3| 51.2| 56.7| 39.2| 36.4| 32.9| <0.001  |
| Supermarket or convenience store | 7.5| 10.0| 14.3| 8.3 | 5.5 | 2.8 | 5.6 | <0.001  |
| Clinic                   | 6.7 | 13.1| 7.9 | 8.3 | 9.2 | 1.4 | 2.8 | <0.001  |
| Beauty salon             | 3.8 | 3.1 | 7.9 | 5.5 | 3.7 | 0.5 | 1.9 | 0.001   |
| Internet                 | 57.5| 36.9| 45.3| 55.3| 59.4| 72.8| 66.2| <0.001  |
| Mail order               | 9.9 | 10.0| 12.3| 11.5| 8.3 | 4.1 | 13.4| 0.018   |
| Family, friends, or acquaintances | 2.8| 4.6 | 4.4 | 5.1 | 2.3 | 0.5 | 0.9 | 0.011   |
| Other                    | 1.0 | 0.0 | 1.0 | 1.4 | 0.5 | 0.9 | 1.9 | 0.569   |

n = 1200. Multiple answers. The difference among generations was examined using a chi-square ($\chi^2$) test.

3.9. Adverse Events

Adverse events that might be associated with estrogen-like dietary supplement use are shown in Table 13. The major adverse event was nausea/vomiting (4.7%), followed by diarrhea/constipation (3.6%) and breast swelling and pain (2.6%). We also asked about supplement use after having experienced adverse events. When they had experienced palpitation/shortness of breath, irregular vaginal bleeding, or eczema/itching, more than half of subjects stopped immediately. However, when they had experienced breast swelling and pain, heavy menstruation, and hot flashes, a lot of them kept using the supplements without changing or decreasing the amount or frequency.

Table 13. Adverse events that might be associated with estrogen-like supplement use.

| Event                                      | n   | %   | Stopped Immediately | Decreased Amount/Frequency | Kept Using |
|--------------------------------------------|-----|-----|---------------------|---------------------------|------------|
| None                                       | 1004| 83.7|                     |                           |            |
| Nausea or vomiting                         | 56  | 4.7 | 42.9                | 37.5                      | 19.6       |
| Headaches                                  | 32  | 2.7 | 46.9                | 37.5                      | 15.6       |
| Diarrhea or constipation                   | 43  | 3.6 | 37.2                | 44.2                      | 18.6       |
| Eczema or itching                          | 18  | 1.5 | 55.6                | 38.9                      | 5.6        |
| Hot flash                                  | 28  | 2.3 | 35.7                | 39.3                      | 25.0       |
| Dizzy                                      | 22  | 1.8 | 40.9                | 36.4                      | 22.7       |
| Fatigue                                    | 23  | 1.9 | 43.5                | 39.1                      | 17.4       |
| Palpitations or shortness of breath        | 12  | 1.0 | 66.7                | 33.3                      | 0.0        |
| Irregular vaginal bleeding                 | 20  | 1.7 | 65.0                | 25.0                      | 10.0       |
| Breast swelling and pain                   | 31  | 2.6 | 29.0                | 22.6                      | 48.4       |
| Heavy menstruation                         | 28  | 2.3 | 32.1                | 39.3                      | 28.6       |
| Other                                      | 11  | 0.9 | 18.2                | 18.2                      | 63.6       |

n = 1200. Multiple answers.

4. Discussion

In 2017, a lot of adverse events associated with use of supplements containing *P. mirifica* were reported to the National Consumer Affairs Center of Japan [7]. The major adverse events included irregular menstruation and vaginal bleeding, potentially caused by the estrogenic effects of *P. mirifica*. In addition to *P. mirifica*, there are several other estrogen-like supplements on the Japanese market, resulting in a risk of adverse events if consumers use them inappropriately. To clarify this issue, we conducted an Internet survey regarding estrogen-like supplement usage. In this study, the prevalence of estrogen-like supplement use was 5%, accounting for approximately 15% of the total sample, including ex-users; the most popular ingredients were soybeans/isoﬂavones. Among them, 16.3% of the participants had experienced adverse events, including symptoms mainly related to physiological effects peculiar to women, such as irregular vaginal bleeding.

We clarified that the prevalence of estrogen-like supplement usage was associated with age, menstruation and menopause conditions, and related problems. Under-menstruation
(premenopausal) was a negative factor of estrogen-like supplement use (OR = 0.75, 95% CI = 0.64–0.86); in other words, menopause was one of the factors for estrogen-like supplement usage. In addition, menstruation-related problems (OR = 1.40, 95% CI = 1.24–1.58) and menopause symptoms (OR = 2.54, 95% CI = 2.34–2.75) were factors of estrogen-like supplement use. Consistently, more than 30% of those aged between their teens and 40s used such supplements for the treatment for menstruation-related symptoms, and more than 50% of those in their 50s–60s used them for the treatment of menopause symptoms. This trend could be explained by the age at onset of menopause. It has been reported that the average age of menopause is 48.3 years old in Japan [27] and 51 years old in the USA [28], and 75% of these women are annoyed by symptoms such as hot flashes and night sweats [28]. Post-menopausal women desire to alleviate these symptoms, such as hot flashes, sleep problems, mood disorders, sexual dysfunction, weight gain, and declines in cognitive functioning, and hormone-replacement therapy is an effective treatment for such problematic symptoms. However, there are potentially undesirable health consequences of hormone-replacement therapy in terms of cardiovascular health and the risk of ovarian and breast cancer [29,30]; thus, a lot of post-menopausal women desire to alleviate these symptoms and seek out complementary and alternative medicine, including phytoestrogens [15,31–34].

In addition, numerous participants used estrogen-like supplements for weight loss and mastogenic effects. In the case of weight loss, 20.0% of the participants, especially those of the younger generations (33.8% in their 10s; 34.5% in their 20s), used estrogen-like supplements for this purpose (Table 7). At this time, there is limited evidence of the efficacy of phytoestrogens on body weight. It has been reported that soy products decrease the body weight, BMI, and body fat ratio in overweight or obese Asian populations [35]. In contrast, however, one systematic review showed no association between phytoestrogen supplementation (e.g., soy isoflavones, daidzein, red clover isoflavones, and flaxseed extract) and body weight, body mass index, waist-to-hip circumference, total fat mass, or percentage of body fat in post-menopausal women [36]. In this regard, there is not enough evidence to encourage the use of estrogen-like supplements for this purpose. In the case of mastogenic effect, 15.7% of the participants (40.0% in their 10s; 37.4% in their 20s) used estrogen-like supplements for this purpose. *P. mirifica* is the most popular ingredient for this purpose in Japan. *P. mirifica* contains a lot of phytoestrogens; miroestrol and deoxymiroestrol are known to be responsible ingredients due to their estrogenic activity [5]. Even though the estrogenic activities of miroestrol and deoxymiroestrol are almost same as those of 17beta-stradiol, quality control has not been conducted on products containing *P. mirifica* which claim mastogenic effects. This situation has caused adverse events in many young women. In light of this, the Japanese government has specified *P. mirifica* as a “Designated Ingredient, etc.” [37]. However, various *P. mirifica* products with attractive claims for women are still on the market, and adverse events are constantly being reported [38].

Soybeans/isoflavones were the most popular ingredients in this survey; there are several studies about the efficacy of soybeans/isoflavones via estrogenic activity on not only menopausal symptoms, but also breast cancer, prostate cancer, cardiovascular diseases, and osteoporosis [39]. In addition, it is reported that isoflavones combination with probiotics improved bone mineral density in postmenopausal women [40]. Prebiotics not only affect the balance of the intestinal flora—this alteration increases the absorption of minerals such as calcium and magnesium, and influences inflammation and the immune system, affecting bone metabolism [41]—but also increase the bioavailability of isoflavones [40]. Probiotics and isoflavones might coordinately prevent osteoporosis. Equol was the second most popular ingredient in this survey. Equol is a metabolite of daidzein which is a soybean isoflavone, and it is produced through intestinal bacterial metabolism [42,43]. There are many reports about the beneficial characteristics of equol products. However, it is also known that approximately 50% of Asians and 25% of non-Asians host the intestinal bacteria that convert daidzein into equol [44]. In addition to soy isoflavones, the market for equol products as supplements has expanded, and studies about equol intake are ongoing.
Beneficial effects of equol intake on hot flashes in postmenopausal women have been reported [45], but there is little scientific evidence of the beneficial effects of equol, other than on menopausal symptoms.

We previously reported that patients use dietary supplements in combination with medicines for the purpose of treating diseases, among other reasons [23,46]. The interaction between dietary supplements and medicines is an important issue among patients. In this survey, 20.8% of the participants were taking medicine for menstruation-related symptoms, and these participants were potentially taking medicines that include estrogen preparations [23,24]. In this situation, pharmacodynamic interactions should be taken into consideration. In contrast, 16.4% of the participants were taking medicine for purposes other than menstruation-related symptoms. In this situation, pharmacokinetic interactions should be considered. It has been reported that soybeans/isoflavones [47], equol [48], black cohosh [49], and other herbal ingredients of dietary supplements have the potential to interact with drugs via the modification of drug metabolism [50,51]; their concomitant use can cause serious adverse events [52]. In this survey, we did not ask what kind of medicines the participants were taking; thus, we cannot speculate on the exact risks to our participants. However, we should consider the possibility that some users of estrogen-like supplements may be deterred from appropriate medical care and appropriate self-care.

The strength of this study is that it is the first report clarifying the perceptions of estrogen-like supplement use. In addition, this survey was conducted on 61,021 participants and 1200 estrogen-like supplement users in each generation. In contrast, a limitation of this study is that it was an online survey; thus, the participants were registrants of the survey company. In this regard, we have to carefully treat our data as general, even though Internet and online questionnaires have become popular across all age groups. In addition, 20.8% of the estrogen supplement users were taking medicine for menstruation-related symptoms, and 16.4% of the estrogen supplement users were taking medicine for reasons other than menstruation-related symptoms. However, we did not ask what kind of medicines they were taking, so we could not examine the risk of the adverse events by concomitant use. In addition, the participants were limited to females only. Although phytoestrogens exert health benefits for not only women, but also men, there is not enough evidence of their efficacy and safety or their potential to cause adverse effects [53]. Recently, the demand for estrogen-like supplements among men [54] and trans people [55] has also increased; thus, we should clarify the situation among these populations.

5. Conclusions
In this study, the use of supplements with estrogen-like effects was observed in all age groups, and it was clarified that the purpose of use differed according to age group. In addition, health hazards, particularly symptoms attributed to female hormone-like effects, are observed at a certain rate, and the possibility of interactions between estrogen-like supplements and medicines is suspected. Thus, it is necessary to pay attention to the use of these products. The purpose of use differs depending on age; therefore, it is considered necessary to provide information according to each age.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14214509/s1, Supplementary Materials.

Author Contributions: Conceptualization, T.C., Y.T. and C.N.; data curation, T.C.; formal analysis, T.C. and C.N.; funding acquisition, T.C. and K.U.; investigation, T.C.; methodology, T.C. and Y.T.; project administration, T.C.; writing—original draft, T.C.; writing—review and editing, T.C., Y.T., C.N. and K.U. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Health, Labour and Welfare Policy Research Grants (grant number H30-shyokuhin-shitei-002 on 1 April 2018), 20KA2002 on 1 April 2021.

Institutional Review Board Statement: This study was conducted with the approval of the Research Ethics Committee of the National Institutes of Biomedical Innovation, Health and Nutrition (No. 13-6, approved on 26 January 2019), and in accordance with the Declaration of Helsinki.
Informed Consent Statement: Informed consent was obtained from all of the participants involved in this study.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Keshavarz, P.; Shafiee, M.; Islam, N.; Whiting, S.J.; Vatanparast, H. Prevalence of vitamin-mineral supplement use and associated factors among Canadians: Results from the 2015 Canadian Community Health Survey. Appl. Physiol. Nutr. Metab. 2021, 46, 1370–1377. [CrossRef]  
2. Bailey, R.L.; Gahche, J.J.; Miller, P.E.; Thomas, P.R.; Dwyer, J.T. Why US adults use dietary supplements. JAMA Intern. Med. 2013, 173, 355–361. [CrossRef] [PubMed]  
3. Austin, S.B.; Yu, K.; Liu, S.H.; Dong, F.; Teft, N. Household expenditures on dietary supplements sold for weight loss, muscle building, and sexual function: Disproportionate burden by gender and income. Prev. Med. Rep. 2017, 6, 236–241. [CrossRef] [PubMed]  
4. Mazur, W. Phytoestrogen content in foods. Baillière’s Clin. Endocrinol. Metab. 1998, 12, 729–742. [CrossRef]  
5. Matsumura, A.; Ghosh, A.; Pope, G.S.; Darbre, P.D. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 94, 431–443. [CrossRef]  
6. Malaiwijnendon, S. Medical applications of phytoestrogens from the Thai herb Pueraria mirifica. Front. Med. 2012, 6, 8–21. [CrossRef]  
7. National Consumer Affairs Center of Japan. Dietary Supplements Containing “Pueraria Mirifica” for Beauty Purposes. Available online: https://www.kokusen.go.jp/news/data/n-20170713_1.html (accessed on 10 September 2022).  
8. Chiba, T.; Tanemura, N.; Nishijima, C.; Umegaki, K. Recognition and Prevalence of “Designated Ingredient, etc.” in Health Foods. J. Food Hyg. Soc. Jpn. 2022, 63, 20–26. [CrossRef]  
9. Lamlertkittikul, S.; Chandy, V. Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study. J. Med. Assoc. Thai. 2004, 87, 33–40.  
10. Wakai, K.; Egami, I.; Kato, K.; Kawamura, T.; Tamakoshi, A.; Lin, Y.; Nakayama, T.; Wada, M.; Ohno, Y. Dietary Intake and Sources of Isoflavones Among Japanese. Nutr. Cancer 1999, 33, 139–145. [CrossRef]  
11. Watanabe, S.; Uehara, M. Health effects and safety of soy and isoflavones. In The Role of Functional Food Security in Global Health; Elsevier: Amsterdam, The Netherlands, 2019; pp. 379–394.  
12. Wei, P.; Liu, M.; Chen, Y.; Chen, D.C. Systematic review of soy isoflavones supplements on osteoporosis in women. Asian Pac. J. Trop. Med. 2012, 5, 243–248. [CrossRef]  
13. Boutas, I.; Kountourgiorgi, A.; Dimitrakakis, C.; Kalantaridou, S.N. Soy Isoflavones and Breast Cancer Risk: A Meta-analysis. In Vivo 2022, 36, 556–562. [CrossRef]  
14. Chen, M.N.; Lin, C.C.; Liu, C.F. Efficacy of phytoestrogens for menopausal symptoms: A meta-analysis and systematic review. Climacteric 2015, 18, 260–269. [CrossRef]  
15. Franco, O.H.; Chowdhury, R.; Troop, J.; Voortman, T.; Kunutsor, S.; Kavousi, M.; Oliver-Williams, C.; Muka, T. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. JAMA 2016, 315, 2554–2563. [CrossRef]  
16. Saghafi, N.; Ghazanfarpoor, M.; Sadeghi, R.; Hosseini Najarkolaei, A.; Ghaffarian Omid, M.; Azad, A.; Bakhtiyari, M.; Hosseini Najarkolaei, E. Effects of Phytoestrogens in Alleviating the Menopausal Symptoms: A Systematic Review and Meta-Analysis. Iran J. Pharm. Res. 2017, 16, 99–111.  
17. Pisani, P.; Renna, M.D.; Conversano, F.; Casciaro, E.; Di Paola, M.; Quarta, E.; Muratore, M.; Casciaro, S. Major osteoporotic fragility fractures: Risk factor updates and societal impact. World J. Orthop. 2016, 7, 171–181. [CrossRef]  
18. Yoshimura, N.; Muraki, S.; Oka, H.; Mabuchi, A.; En-Yo, Y.; Yoshida, M.; Saika, A.; Yoshida, H.; Suzuki, T.; Yamamoto, S.; et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: The research on osteoarthritis/osteoporosis against disability study. J. Bone Miner. Metab. 2009, 27, 620–629. [CrossRef]  
19. Tella, S.H.; Gallagher, J.C. Prevention and treatment of postmenopausal osteoporosis. J. Steroid Biochem. Mol. Biol. 2014, 142, 155–170. [CrossRef]  
20. Cauley, J.A.; Robbins, J.; Chen, Z.; Cummings, S.R.; Jackson, R.D.; LaCroix, A.Z.; LeBoff, M.; Lewis, C.E.; McGowan, J.; Neuner, J.; et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women’s Health Initiative randomized trial. JAMA 2003, 290, 1729–1738. [CrossRef]  
21. Beral, V.; Gaitskell, K.; Hermon, C.; Moser, K.; Reeves, G.; Petö, R. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet 2015, 385, 1835–1842. [CrossRef]  
22. Shi, L.F.; Wu, Y.; Li, C.Y. Hormone therapy and risk of ovarian cancer in postmenopausal women: A systematic review and meta-analysis. Menopause 2016, 23, 417–424. [CrossRef]  
23. Chiba, T.; Sato, Y.; Suzuki, S.; Umegaki, K. Concomitant use of dietary supplements and medicines in patients due to miscommunication with physicians in Japan. Nutrients 2015, 7, 2947–2960. [CrossRef]
24. Nahin, R.L.; Pecha, M.; Welmerink, D.B.; Sink, K.; DeKosky, S.T.; Fitzpatrick, A.L. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J. Am. Geriatr. Soc. 2009, 57, 1197–1205. [CrossRef] [PubMed]

25. Halli-Tierney, A.D.; Scarborough, C.; Carroll, D. Polypharmacy: Evaluating Risks and Deprescribing. Am. Fam. Physician 2019, 100, 32–38. [PubMed]

26. Zabłocka-Słowinska, K.; Jawna, K.; Grajeta, H.; Biernat, J. Interactions between preparations containing female sex hormones and dietary supplements. Adv. Clin. Exp. Med. 2014, 23, 657–663. [CrossRef] [PubMed]

27. Amagai, Y.; Ishikawa, S.; Gotoh, T.; Kayaba, K.; Nakamura, Y.; Kajii, E. Age at menopause and mortality in Japan: The Jichi Medical School Cohort Study. J. Epidemiol. 2006, 16, 161–166. [CrossRef]

28. Shufelt, C.; Manson, J. Managing Menopause by Combining Evidence with Clinical Judgment. Clin. Obstet. Gynecol. 2018, 61, 470–479. [CrossRef]

29. Zhang, G.Q.; Chen, J.L.; Luo, Y.; Mathur, M.B.; Anagnostis, P.; Nurmatov, U.; Talibov, M.; Zhang, J.; Hawrylowicz, C.M.; Lumsden, M.A.; et al. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Med. 2021, 18, e1003731. [CrossRef]

30. Temkin, S.M.; Mallen, A.; Bellavance, E.; Rubinsak, L.; Wenham, R.M. The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer 2019, 125, 499–514. [CrossRef]

31. Girardi, A.; Piccinni, C.; Raschi, E.; Koci, A.; Vitamia, B.; Poluzzi, E.; De Ponti, F. Use of phytoestrogens and effects perceived by postmenopausal women: Result of a questionnaire-based survey. BMC Complement. Altern. Med. 2014, 14, 262. [CrossRef]

32. Posadzki, P.; Lee, M.S.; Moon, T.W.; Choi, T.Y.; Park, T.Y.; Ernst, E. Prevalence of complementary and alternative medicine (CAM) use by menopausal women: A systematic review of surveys. Maturitas 2013, 75, 34–43. [CrossRef]

33. Gentry-Maharaj, A.; Karpinskiy, C.; Glazer, C.; Burnell, M.; Bailey, K.; Apostolidou, S.; Ryan, A.; Lanceley, A.; Fraser, L.; Jacobs, M.A.; et al. Menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening. Climacteric 2017, 20, 240–247. [CrossRef]

34. Costanian, C.; Christensen, R.A.G.; Edgell, H.; Ardern, C.I.; Tamim, H.; Jacobs, M.A.; et al. Menopausal hormone therapy and women’s health: An umbrella review. Planta Med. 2020, 86, 421–426. [CrossRef]

35. Mu, Y.; Kuo, T.; Wei, B.; Lu, X.; Liu, J.; Tian, H.; Zhang, W.; Liu, B.; Li, H.; Cui, W.; et al. Soy Products Ameliorate Obesity-Related Anthropometric Indicators in Overweight or Obese Asian and Non-Menopausal Women: A Meta-Analysis of Randomized Controlled Trials. Nutrients 2019, 11, 2790. [CrossRef]

36. Glisic, M.; Kastrati, N.; Musa, J.; Milic, J.; Asllanaj, E.; Portilla Fernandez, E.; Nano, J.; Ochoa Rosales, C.; Amiri, M.; Kraja, B.; et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women: A randomized controlled trial. Molecules 2019, 24, 1003731. [CrossRef]

37. Ministry of Health, Labour and Welfare. Designated Ingredient, etc. (Related Laws and Regulations). Available online: https://mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/syokuchu/04_00003.html (accessed on 10 September 2022).

38. Ministry of Health, Labour and Welfare. Designated Ingredient, etc. (Adverse Events Reports). Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/hokenkinou/kankeihourei_00001.html (accessed on 10 September 2022).

39. Křížová, L.; Dadáková, K.; Kašparovská, J.; Kašparovský, T. Isoflavones. Molecules 2019, 24, 1076. [CrossRef]

40. Křížová, L.; Dadáková, K.; Kašparovská, J.; Kašparovský, T.; Seidlová, M. Dietary supplements. Molecules 2019, 24, 1076. [CrossRef]

41. Lambert, M.N.T.; Thybo, C.B.; Lykkeboe, S.; Rasmussen, L.M.; Frette, X.; Christensen, L.P.; Jeppesen, P.B. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: A randomized controlled trial. Am. J. Clin. Nutr. 2017, 106, 909–920. [CrossRef]

42. De Sire, A.; de Sire, R.; Curci, C.; Castiglione, F.; Wahli, W. Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis. Cells 2022, 11, 743. [CrossRef]

43. Bolca, S.; Possemiers, S.; Herregat, A.; Huybrechts, I.; Heyerick, A.; De Vriese, S.; Verbruggen, M.; Depypere, H.; De Keukeleire, D.; Bracke, M.; et al. Microbial and dietary factors are associated with the equal producer phenotype in healthy postmenopausal women. Nutrients 2007, 137, 2242–2246. [CrossRef]

44. Kim, S.H.; Lee, S.H.; Park, S.H.; Park, H.; Han, J.H.; Lee, S.H.; Kim, T. Equol Decreases Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2019, 11, 2790. [CrossRef]

45. Utian, W.H.; Jones, M.; Setchell, K.D. S-equol: A potential nonhormonal agent for menopause-related symptom relief. J. Women’s Health 2015, 24, 200–208. [CrossRef]

46. Křížová, L.; Dadáková, K.; Kašparovská, J.; Kašparovský, T. Isoflavones. Molecules 2019, 24, 1076. [CrossRef]

47. Gorman, G.S.; Coward, L.; Darby, A.; Rasberry, B. Effects of herbal supplements on the bioactivation of chemotherapeutic agents. J. Pharm. Pharmacol. 2013, 65, 1014–1025. [CrossRef]

48. Gurley, B.J. Pharmacokinetic herb-drug interactions (part 1): Origins, mechanisms, and the impact of botanical dietary supplements. Planta Med. 2012, 78, 1478–1489. [CrossRef]
51. Gurley, B.J.; Fifer, E.K.; Gardner, Z. Pharmacokinetic herb-drug interactions (part 2): Drug interactions involving popular botanical dietary supplements and their clinical relevance. *Planta Med.* 2012, 78, 1490–1514. [CrossRef]

52. Tsai, H.H.; Lin, H.W.; Simon Pickard, A.; Tsai, H.Y.; Mahady, G.B. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: A systematic literature review. *Int. J. Clin. Pract.* 2012, 66, 1056–1078. [CrossRef]

53. Rietjens, I.; Louisse, J.; Beekmann, K. The potential health effects of dietary phytoestrogens. *Br. J. Pharmacol.* 2017, 174, 1263–1280. [CrossRef]

54. Zhang, M.; Wang, K.; Chen, L.; Yin, B.; Song, Y. Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases. *Andrology* 2016, 4, 745–756. [CrossRef]

55. Rotondi, N.K.; Bauer, G.R.; Scanlon, K.; Kaay, M.; Travers, R.; Travers, A. Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. *Am. J. Public Health* 2013, 103, 1830–1836. [CrossRef]